MDXG - MiMedx completes patient visits in late-stage musculoskeletal trials

MiMedx (MDXG) announces that the last patients have completed their clinical visits in two late-stage trials of AmnioFix Injectable as a potential treatment for Plantar Fasciitis and Achilles Tendonitis.In addition, all clinical effectiveness endpoint visits have been completed in a Phase 2B study of mdHACM as a potential treatment for Knee Osteoarthritis.The company will begin the planned review and statistical analyses of data from all three trials, with topline results expected in Q3 2021.MiMedx has also commenced planning efforts to initiate a Phase 3 clinical trial for Knee Osteoarthritis, and plan to file a Biologics License Application ((BLA)) for Plantar Fasciitis in the first half of 2022.

For further details see:

MiMedx completes patient visits in late-stage musculoskeletal trials